Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-Rendelointezet

The Varmegyei Onkologiai Kozpont in Szolnok is highly active in neoplasms, with a strong focus on breast cancer, non-small cell lung cancer, small cell lung cancer, urothelial cancer, melanoma, and gastric cancer. These studies are mainly designed to test new cancer therapies, compare them with current standards, and improve survival and disease control.

• Advanced breast cancer, including HER2-positive, HER2-low, and hormone receptor-positive disease
• Non-small cell lung cancer and small cell lung cancer across early, locally advanced, and metastatic settings
• Urothelial cancer, prostate cancer, renal cell carcinoma, and other solid tumors

Much of the research at this site centers on evaluating whether newer targeted and immune-based treatments can improve outcomes for patients with difficult-to-treat cancers.

Clinical trials in hemic and lymphatic diseases include studies of cancers and blood-related conditions that affect how blood cells grow and function. The research explores better treatment options and more effective disease control for patients with advanced or resistant illness.

• Hematologic malignancies and lymphatic cancers
• Metastatic castration-resistant prostate cancer and other advanced cancers with blood-related treatment needs
• Trials aiming to improve response rates, survival, and long-term disease management

These studies reflect a broader effort at Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-Rendelointezet to expand treatment choices for patients with complex cancer diagnoses.

The site also supports research in cardiovascular diseases and nutritional and metabolic diseases, including atherosclerotic cardiovascular disease, heart failure, hyperlipidemia, atrial fibrillation, obesity, and type 2 diabetes mellitus. These trials are focused on preventing complications, reducing risk, and improving day-to-day disease control.

• Atherosclerotic cardiovascular disease and prevention of major heart and stroke events
• Heart failure, including forms linked with obesity and preserved ejection fraction
• Type 2 diabetes, obesity, and lipid disorders such as hyperlipidemia

Research in these areas is aimed at finding safer and more effective ways to lower cardiovascular risk and support metabolic health.

Another major area of work is respiratory tract diseases, especially chronic obstructive pulmonary disease, asthma, and lung cancer-related care. The trials are designed to improve symptom control, reduce flare-ups, and evaluate treatments that may better support breathing and lung function.

• Chronic obstructive pulmonary disease and chronic bronchitis
• Mild to moderate asthma and exacerbation prevention
• Lung cancer studies that overlap with respiratory oncology care

At this hospital-based research setting, respiratory studies often examine whether new therapies can improve quality of life while addressing serious long-term lung conditions.

The site’s broader portfolio includes environment and public health research and trials involving overlapping conditions such as chronic kidney disease, thromboembolic disease, and cardiometabolic risk. These studies look at ways to prevent worsening illness and improve outcomes across multiple organ systems.

• Chronic kidney disease with hypertension and cardiovascular risk
• Thromboembolic disease and prevention of serious clot-related events
• Studies addressing patients with more than one long-term condition

This research reflects a practical clinical focus on reducing complications in patients whose health needs extend beyond a single disease area.